A Study to Assess the Cognitive Effects of Fesoterodine in Elderly Subjects
This study has been completed.
Sponsor:
Pfizer
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01161472
First received: July 12, 2010
Last updated: May 25, 2012
Last verified: May 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The study is designed to evaluate elements of cognitive function in subjects receiving either fesoterodine or alprazolam.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Drug: 4mg fesoterodine Drug: 8mg fesoterodine Drug: alprazolam 1mg Drug: Placebo |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) |
| Official Title: | A 4 Way Placebo And Active Controlled Study To Evaluate The Effects Of Fesoterodine On Cognitive Function In Healthy Elderly Subjects |
Resource links provided by NLM:
Further study details as provided by Pfizer:
Primary Outcome Measures:
- Computer Based Objective Cognition Testing (CogState) Detection Speed [ Time Frame: Baseline ] [ Designated as safety issue: No ]Detection speed: a cognitive test which assessed psychomotor function. A playing card was presented face up in the center of the screen. As soon as this happened, the participant was to press the 'Yes' key. The outcome measure was speed of performance; mean of the log10 transformed reaction time for correct responses [measured in log10 milliseconds (MS)]. Lower scores meant a better performance.
- Change From Baseline in Computer Based Objective Cognition Testing (CogState) Detection Speed on Day 6 [ Time Frame: Baseline and Day 6 ] [ Designated as safety issue: No ]Detection speed: a cognitive test which assessed psychomotor function. A playing card was presented face up in the center of the screen. As soon as this happened, the participant was to press the 'Yes' key. The outcome measure was speed of performance; mean of the log10 transformed reaction time for correct responses [measured in log10 milliseconds (MS)]. Lower scores meant a better performance.
Secondary Outcome Measures:
- CogState Identification Speed [ Time Frame: Baseline ] [ Designated as safety issue: No ]Identification speed: a cognitive test which assessed visual attention. A playing card was presented face up in the center of the screen. As soon as this happened, the participant had to decide whether the card was red or not. The outcome measure was speed of performance; mean of the log10 transformed reaction time for correct responses (measured in log10 MS). Lower scores meant a better performance.
- Change From Baseline in CogState Identification Speed on Day 6 [ Time Frame: Baseline and Day 6 ] [ Designated as safety issue: No ]Identification speed: a cognitive test which assessed visual attention. A playing card was presented face up in the center of the screen. As soon as this happened, the participant had to decide whether the card was red or not. The outcome measure was speed of performance; mean of the log10 transformed reaction time for correct responses (measured in log10 MS). Lower scores meant a better performance.
- CogState One Card Learning [ Time Frame: Baseline ] [ Designated as safety issue: No ]One card learning: a cognitive test which assessed visual learning. Participants were to remember which cards were previously shown in a task. The outcome measure was accuracy of performance; arcsine transformation of the square root (sqrt) of the proportion of correct responses. Higher scores meant a better performance.
- Change From Baseline in CogState One Card Learning on Day 6 [ Time Frame: Baseline and Day 6 ] [ Designated as safety issue: No ]One card learning: a cognitive test which assessed visual learning. Participants were to remember which cards were previously shown in a task. The outcome measure was accuracy of performance; arcsine transformation of the square root (sqrt) of the proportion of correct responses. Higher scores meant a better performance.
- CogState Continuous Paired Associate Learning (CPAL) [ Time Frame: Baseline ] [ Designated as safety issue: No ]CPAL: a cognitive test which assessed visual episodic learning. Participant was to learn and remember picture locations on the screen and was to tap the target on the central location to begin. As each picture was revealed, the participant was to remember where the picture was located and tap that location. The outcome measure was the number of errors made in correctly placing each of the 4 patterns in their location 4 times. Lower scores meant a better performance.
- Change From Baseline in CogState CPAL on Day 6 [ Time Frame: Baseline and Day 6 ] [ Designated as safety issue: No ]CPAL: a cognitive test which assessed visual episodic learning. Participant was to learn and remember picture locations on the screen and was to tap the target on the central location to begin. As each picture was revealed, the participant was to remember where the picture was located and tap that location. The outcome measure was the number of errors made in correctly placing each of the 4 patterns in their location 4 times. Lower scores meant a better performance.
- CogState Groton Maze Learning Task (GMLT) [ Time Frame: Baseline ] [ Designated as safety issue: No ]GMLT: a cognitive test which assessed executive function. Participant was shown a 10 x 10 grid of tiles on a computer touch screen. A 28-step pathway was hidden among 100 possible locations. The participant was instructed to move 1 step from the start location and then continue 1 tile at a time, toward the end to find the pathway. The outcome measure was total number of errors made in attempting to learn the same hidden pathway on 5 consecutive trials at a single session. Lower scores meant a better performance.
- Change From Baseline in CogState Groton Maze Learning Task on Day 6 [ Time Frame: Baseline and Day 6 ] [ Designated as safety issue: No ]GMLT: a cognitive test which assessed executive function. Participant was shown a 10 x 10 grid of tiles on a computer touch screen. A 28-step pathway was hidden among 100 possible locations. The participant was instructed to move 1 step from the start location and then continue 1 tile at a time, toward the end to find the pathway. The outcome measure was total number of errors made in attempting to learn the same hidden pathway on 5 consecutive trials at a single session. Lower scores meant a better performance.
- Rey Auditory Verbal Learning Test (RAVLT) [ Time Frame: Baseline ] [ Designated as safety issue: No ]RAVLT evaluates a wide diversity of functions: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval. Assessment of RAVLT is between 10 to 15 minutes; Performance variable: the sum of the number of words recalled successfully on the delayed recall trial. Higher score meant a better performance.
- Rey Auditory Verbal Learning Test (RAVLT) on Day 6 [ Time Frame: Baseline and Day 6 ] [ Designated as safety issue: No ]RAVLT evaluates a wide diversity of functions: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval. Assessment of RAVLT is between 10 to 15 minutes; Performance variable: the sum of the number of words recalled successfully on the delayed recall trial. Higher score meant a better performance.
| Enrollment: | 20 |
| Study Start Date: | July 2010 |
| Study Completion Date: | September 2010 |
| Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: 4mg fesoterodine |
Drug: 4mg fesoterodine
4mg tablet once daily for 6 days
|
| Experimental: fesoterodine 8mg |
Drug: 8mg fesoterodine
4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days
|
| Active Comparator: 1mg alprazolam |
Drug: alprazolam 1mg
1mg tablet once on last day of treatment period at clinic
|
| Placebo Comparator: Placebo |
Drug: Placebo
Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
|
Detailed Description:
Evaluation of cognitive function
Eligibility| Ages Eligible for Study: | 65 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Adult healthy volunteers 65 years and over with minimum MMSE of 26
Exclusion Criteria:
- Prohibited concomitant medications
- Confounding medical conditions
- Clinically significant comorbid diseases
- Hypersensitivity or contraindications to fesoterodine or active control
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01161472
Locations
| United States, Kansas | |
| Pfizer Investigational Site | |
| Overland Park, Kansas, United States, 66212 | |
| Pfizer Investigational Site | |
| Overland Park, Kansas, United States, 66211 | |
Sponsors and Collaborators
Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
Additional Information:
No publications provided
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT01161472 History of Changes |
| Other Study ID Numbers: | A0221086 |
| Study First Received: | July 12, 2010 |
| Results First Received: | May 25, 2012 |
| Last Updated: | May 25, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Alprazolam Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses |
Anti-Anxiety Agents Tranquilizing Agents Psychotropic Drugs GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 21, 2013